Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KV23a
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : GEM Global Yield
Deal Size : $120.0 million
Deal Type : Financing
Kensana Lands $120 Million from GEM, Fuelling a Global Plant Based Medicine Revolution
Details : The proceeds will be used to advance the clinical development of its lead botanical candidate KV23A, which is being positioned to enter a registerable Phase 3 program.
Product Name : KV23a
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
September 19, 2025
Lead Product(s) : KV23a
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : GEM Global Yield
Deal Size : $120.0 million
Deal Type : Financing